US-based biotechnology company BioMarin Pharmaceutical has announced the completion of an underwritten public offering of senior subordinated convertible notes to raise $450m.
The notes carry a rate of 0.599% and are due on 1 August 2024.
Go deeper with GlobalData
BioMarin plans to use the funds to repay debt, repurchase notes due in October 2018, as well as for general corporate purposes.
Spectrum Pharmaceuticals plans for a private placement of shares to raise up to $150m.
The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.
See Also:
Chinese pharmaceutical company Orient Pharma plans to issue 21 million common stock shares priced at NT$20 ($D0.6) each to raise NT$425m ($14.06m).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company plans to use the funds towards loan repayment and for working capital purposes.
